Entries |
Document | Title | Date |
20100249022 | STRATEGY FOR CLONING AND EXPRESSING THE EXTRACELLULAR DOMAINS OF RECEPTORS AS SOLUBLE PROTEINS - The present invention relates generally to soluble G protein-coupled receptor constructs. More specifically, the invention relates to soluble chemokine receptors, and soluble HIV co-receptors in particular. The invention is generally useful for designing and constructing soluble GPCR, which may be used to identify binding molecules. The invention also relates to methods of treating and/or preventing a disease or disorder associated with impaired function of such a receptor. The invention thus provides compositions and methods for therapeutic applications, such as vaccine. | 09-30-2010 |
20100261641 | SPIRO-PIPERIDINE COMPOUNDS AND MEDICINAL USE THEREOF - The present invention relates to a spiro-piperidine compound represented by formula (I): | 10-14-2010 |
20100286032 | PRODRUGS OF HIV PROTEASE INHIBITORS - A compound of the formula | 11-11-2010 |
20100298209 | COMPOUNDS FOR PREVENTING OR TREATING A VIRAL INFECTION - The invention which is the subject of the present application relates to a compound of structure I: A-B-C for use in the prophylaxis and/or treatment of a viral infection, and in particular for preventing and/or inhibiting viral replication, in which A is a quinoline or a quinoline-type group, B is a single amino acid or a peptide or polypeptide having a given amino acid sequence, C is an O-phenoxy group and the symbol “-” indicates that the entities A, B and C are chemically bonded within the compound I. | 11-25-2010 |
20100305028 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION - The present invention relates to compounds comprising at least ten contigous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus. | 12-02-2010 |
20110003735 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION - This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections. | 01-06-2011 |
20110028387 | METHODS OF SCREENING OF PP1-INTERACTING POLYPEPTIDES OR PROTEINS, PEPTIDES INHIBITING PP1c BINDING TO Bcl-2 PROTEINS, BCL-XL AND BCL-W, AND USES THEREOF - The invention relates to methods for identifying novel PP1-interacting polypeptides and proteins, compounds which are able to inhibit the binding of PP1c to certain factors naturally interacting with it, especially proteins of the Bcl-2 family (such as Bcl-x | 02-03-2011 |
20110028388 | DOUBLE-STRANDED POLYETHYLENE GLYCOL MODIFIED GROWTH HORMONE, PREPARATION METHOD AND APPLICATION THEREOF - The growth hormone with high biological activity modified by the double-stranded polyethylene glycol at a single site and the preparation method thereof are provided. The PEGylated growth hormone has a higher biological activity and a longer half-life than the unmodified growth hormone. The composition comprising the PEGylated growth hormone is useful in the treatment of the growth or development disorder such as growth hormone deficiency, Turner syndrome etc. | 02-03-2011 |
20110039765 | Bioactive Molecules Produced by Probiotic Bacteria - The present invention is a method for isolating bioactive molecules secreted by probiotic bacteria such as | 02-17-2011 |
20110046043 | CONTROL OF VIRAL-HOST MEMBRANE FUSION WITH HYDROGEN BOND SURROGATE-BASED ARTIFICIAL HELICES - The present invention relates to a peptide having one or more stable, internally-constrained HBS α-helices, where the peptide mimics at least a portion of a class I C-peptide helix or at least a portion of a class I N-peptide helix of a viral (e.g., HIV-I) coiled-coil assembly. Methods of inhibiting viral infectivity of a subject by administering these peptides are also disclosed. | 02-24-2011 |
20110082075 | Anti-viral fusion peptides - Hybrid peptides capable of binding a blood borne virus to a red cell, comprising a viral binding peptide component and a malaria merozoite red cell peptide binding component. | 04-07-2011 |
20110098215 | PEPTIDES AND METHODS OF USE AS THERAPEUTICS AND SCREENING AGENTS - Host RNA/viral protein interaction as a target of intervention in the replication of viruses, e.g., the human immunodeficiency virus (HIV) are described. The target being upstream of the final replication product, and being crucial to the viral replication, is less likely to be genetically altered to drug resistance. Peptides that intervene in this RNA/viral protein interaction are also described, as well as compositions containing the same and methods of use thereof. | 04-28-2011 |
20110152179 | Method of treating HIV in drug resistant non plasma viral reservoirs with monomeric DAPTA - Residual HIV-1 replication reemerges after intensive therapy from location or locations in the body called the drug resistant non-plasma viral reservoir. Methods are disclosed of treating HIV by inhibiting or blocking this reemergence with various monomeric therapeutic peptide compositions including monomeric DAPTA prepared in least 80% trifluoroethanol, with vigorous shaking for at least about 24 hours at about 37° C. | 06-23-2011 |
20110166061 | LONG LASTING FUSION PEPTIDE INHIBITORS FOR HIV INFECTION - The present invention is concerned with This invention relates to C34 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections. | 07-07-2011 |
20110183894 | ANTIVIRAL ACTIVITY OF THE PROTEIN SCYTOVIRIN AND METHODS OF USE - The present invention features methods of treating or preventing a viral infection in a subject, methods of inhibiting a virus in a biological sample, and methods of treating or preventing a viral infection caused by a virus in or on the skin or mucus membrane. The instant invention describes novel methods for treating viral infections, in particular infections caused by high mannose enveloped viruses, for example hepatitis C virus (HCV). | 07-28-2011 |
20110237501 | Detection of Mutations in a Gene Associated with Resistance to Viral Infection, OAS1 - A method for detecting a mutation related to the gene encoding OAS1. This and other disclosed mutations correlate with resistance of humans to viral infection including hepatitis C. Also provided is a therapeutic agent consisting of a protein or polypeptide encoded by the mutated gene, or a polynucleotide encoding the protein or polypeptide. Inhibitors of human OAS1, including antisense oligonucleotides, methods, and compositions specific for human OAS1, are also provided. | 09-29-2011 |
20110245155 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY - Template-fixed β-hairpin peptidomimetics of the general formula (I) | 10-06-2011 |
20110245156 | NOVEL ANTIVIRAL COMPOUNDS, COMPOSITIONS, AND METHODS OF USE - Compounds are disclosed. Compositions that include the compounds are disclosed. Methods of making and using the compounds are also disclosed. | 10-06-2011 |
20110257082 | HIV-1 INTEGRASE DERIVED STIMULATORY PEPTIDES INTERFERING WITH INTEGRASE -- REV PROTEIN BINDING - Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS. | 10-20-2011 |
20110263485 | Bifunctional Griffithsin Analogs - The present disclosure provides chimeric proteins, protein combinations and other compositions comprising a gp120-binding protein such as Griffithsin. Also provided are methods of using the proteins, protein combinations or compositions to prevent or treat HIV infection. | 10-27-2011 |
20110263486 | Inhibitors of Cancer Cell, T-Cell and Keratinocyte Proliferation - The invention relates to compounds of the general formula (I) and salts and physiologically functional derivatives thereof, | 10-27-2011 |
20110269676 | BIFUNCTIONAL MOLECULES FOR INACTIVATING HIV AND BLOCKING HIV ENTRY - Disclosed herein are bifunctional molecules which inactivate human immunodeficiency virus (HIV) even before the virus attacks the target cell and inhibits HIV entry into the target cell. Also disclosed are novel anti-HIV therapeutics for treatment of patients infected by HIV. Further disclosed are methods for prophylaxis against HIV and treatment of HIV infection. | 11-03-2011 |
20110294727 | COMPOSITIONS OF NUTRITION SUPPLEMENTATION FOR NUTRITIONAL DEFICIENCIES AND METHOD OF USE THEREFORE - A nutritional supplement composition for treating nutritional deficiencies caused by a medical condition in subjects is disclosed. The present application further discloses a method of using a nutritional supplements composition for treating a subject with complications resulting from sickle cell anemia. The method comprises administering to a subject an effective amount of the nutritional supplement. | 12-01-2011 |
20110294728 | Antiviral Polypeptides - The invention concerns polypeptides derived from the HIV-1 reverse transcriptase which are capable of inhibiting said polymerase and optionally also capable of inhibiting the HIV-1 integrase 3′ processing activity, and their therapeutic applications. | 12-01-2011 |
20110312878 | PHARMACOLOGICALLY ACTIVE PEPTIDE CONJUGATES HAVING A REDUCED TENDENCY TOWARDS ENZYMATIC HYDROLYSIS - The invention is directed to a pharmacologically active peptide conjugate having a reduced tendency towards enzymatic cleavage comprising a pharmacologically active peptide sequence (X) and a stabilising peptide sequence (Z) of 4-20 amino acid residues covalently bound to X. | 12-22-2011 |
20110312879 | TEMPLATE-FIXED BETA-HAIRPIN PEPTIDOMIMETICS WITH CXCR4 ANTAGONIZING ACTIVITY - Template-fixed peptidomimetics formula (Ia) formula (Ib) wherein Z is a template-fixed chain of 14 α-amino and/or α-hydroxy acid residues which, depending on their positions in the chain (counted starting from the N-terminal amino acid), are Pro, Gly, a glycolic acid residue or of certain types which, as the remaining symbols in the above formulae, are defined in the description and the claims, and salts thereof, have CXCR4 antagonizing properties and can be used for preventing HIV infections in non-infected individuals or for slowing and halting viral progression in infected patients; or where cancer is mediated or resulting from CXCR4 receptor activity; or where immunological diseases are mediated or resulting from CXCR4 receptor activity; or for treating immuno suppression; or during apheresis collections of peripheral blood stem cells and/or as agents to induce mobilization of stem cells to regulate tissue repair. These depsipeptides can be manufactured by a process which is based on a mixed solid- and solution phase synthetic strategy. | 12-22-2011 |
20110319321 | MAMMALIAN COLOSTRUM DERIVED NANOPEPTIDES FOR BROADSPECTRUM VIRAL AND RECURRENT INFECTIONS WITH A METHOD OF ISOLATION THEREOF - The present invention relates to nanopeptides isolated from mammalian colostrum with vaccine like antiviral and immunodulator activity via building body's own immune system and attachment inhibition on the cell surface receptors. | 12-29-2011 |
20120015874 | NOVEL INHIBITORS OF RETROVIRAL REVERSE TRANSCRIPTACE - Disclosed are nucleic acid molecules, and methods of their use, which have a specific structure including a double helical domain and a G-quadruplex domain physically connected by a linker domain which may be nucleosidic or non-nucleosidic. These aptamers demonstrate potent inhibition of phylogenetically diverse primate lentiviral reverse transcriptases, which effect is largely independent of aptamer sequence provided that the aptamer has the specified structure. | 01-19-2012 |
20120028888 | APJ RECEPTOR COMPOUNDS - The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the intracellular loops and domains of the the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as heart diseases (e.g., hypertension and tension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection. | 02-02-2012 |
20120028889 | INTEGRASE COFACTOR - The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules. | 02-02-2012 |
20120035098 | NOVEL ANTIVIRAL AGENT - The present invention describes the use of a composition including or constituted by at least one element chosen from:
| 02-09-2012 |
20120040891 | HIV FUSION INHIBITOR PEPTIDES WITH IMPROVED BIOLOGICAL PROPERTIES - Provided is an HIV fusion inhibitor peptide having an amino acid sequence of any one of SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, or SEQ ID NO:15; and provided is a pharmaceutical composition comprising a HIV fusion inhibitor peptide and one or more of a pharmaceutically acceptable carrier and macromolecular carrier, and uses and methods of treatment provided by these compositions. | 02-16-2012 |
20120094896 | INHIBITORS OF VIRAL INTEGRASE AND METHODS OF USE - Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors. | 04-19-2012 |
20120108500 | Compositions and Methods for Modulating Immunodeficiency Virus Transcription - The present disclosure provides methods of modulating immunodeficiency virus transcription, involving modulating enzymatic activity and/or levels of a lysine-specific demethylase-1 (LSD1) polypeptide and/or LSD1-mediated demethylation of methylated Tat. The present disclosure also provides method of identifying agents that modulate LSD1-mediated demethylation of a human immunodeficiency virus (HIV) Tat polypeptide. | 05-03-2012 |
20120115775 | MUTANT TAT PROTEINS AND USES THEREOF - Disclosed are viral proteins associated with Human Immunodeficiency Virus (HIV) infections and mutants thereof, particularly, mutant Tat proteins capable of modulating multiple steps of the HIV-1 replication cycle. Also provided are methods of using the mutant Tat proteins, and pharmaceutical compositions comprising the same, for prevention and treatment of HIV-1 infections, and/or symptoms associated therewith. | 05-10-2012 |
20120149633 | MODULATION OF CD4+ T CELL RESPONSES BY A TICK SALIVA PROTEIN, SALP15 AND POLYPEPTIDES DERIVED THEREFROM - Salp15, biologically functional equivalents and fragments thereof, and nucleic acid molecules encoding the same are disclosed. Recombinant host cells, recombinant nucleic acids and recombinant proteins are also disclosed. Salp15 gene products and Salp15 polypeptide fragments have biological activity in modulating CD4+ T cell activation through specific binding to CD4. Thus, therapeutic methods involving modulating T cell activation using Salp15 and biologically active polypeptide fragments thereof are also disclosed. The specific binding of Salp15 and fragment peptides thereof to CD4 can inhibit HIV infection of T cells, and thus methods of using Salp15 for inhibiting HIV infection are also disclosed. Screening methods for selecting substances having an ability to modulate activation of T cells are also disclosed. | 06-14-2012 |
20120165248 | Glutathione Derivatives and Their Uses for the Treatment of Viral Diseases - Glutathione derivatives (GSH) of formula I are provided, wherein R is a thiol protection group. The derivatives are useful for the treatment of infections from Paramyxovirus, Orthomyxovirus, Herpes Simplex Virus and Acquired Immunodeficiency Syndrome Virus. | 06-28-2012 |
20120165249 | Stabilized Therapeutic Small Helical Antiviral Peptides - Provided are constrained peptides that inhibit HIV assembly. Pharmaceutical compositions comprising the above peptides are also provided. Additionally provided are methods of inhibiting replication of a capsid-containing virus. | 06-28-2012 |
20120165250 | Active Cores of Peptide Triazole HIV-1 Entry Inhibitors - The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. Further provided are an antibody to the peptide triazole conjugate, and a method of identifying an HIV-I entry inhibitor candidate. | 06-28-2012 |
20120208745 | TREATMENT OF HIV - We describe methods of treatment of HIV using proopiomelanocortin (POMC) and corticotropin releasing factor (CRF) peptides and their products, as well as uses of such peptides in the preparation of medicaments. | 08-16-2012 |
20120245081 | FAS PEPTIDE MIMETICS AND USES THEREOF - Exocyclic peptide mimetics that disable Fas were developed. A three dimensional model of the Fas receptor-ligand complex was constructed and structurally predicted regions of the receptor that were relevant to binding ligand were used to create constrained peptide mimetics. Exocyclic anti-Fas peptide mimetics were identified that block Fas receptor-ligand interactions, and modulate Fas biological activity both in vitro and in vivo. The mimetics are useful, e.g., for treating Fas-related pathologies. | 09-27-2012 |
20120258908 | OLIGOADENYLATE SYNTHETASE (OAS) - The invention describes novel pharmaceutical compositions for the treatment of virus infections and cancer. The pharmaceutical compositions include mutant oligoadenylate synthetases (OAS) that have either enhanced cell permeability, reduced oxidative potential, improved antiviral activity, improved enzymatic activity, or absent enzymatic activity. The pharmaceutical compositions have improved drug properties and retain or have enhanced antiviral activity relative to their native forms. The pharmaceutical compositions further include chemically modified oligoadenylate synthetases, such chemical modifications being designed to increase serum stability and reduce immunogenicity in vivo. Such chemical modifications further increase drug stability and manufacturability in vitro. Compositions composed of more than ninety novel modifications are described. Also described are antibodies to polypeptides of the invention. | 10-11-2012 |
20120270774 | MACROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND METHODS FOR PREVENTING OR TREATING HIV INFECTION - The present invention relates to backbone cyclized CD-4 mimetics and to compositions and methods comprising them for preventing and treating viral infection. In particular, the present invention relates to orally bio-available compounds and formulations for prevention and treatment of human HIV-1 infection. | 10-25-2012 |
20120277146 | Compounds For Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 11-01-2012 |
20120289459 | ANTIVIRAL PEPTIDES FROM AFRICAN SWINE FEVER VIRUS WHICH PREVENT THE BINDING OF THE VIRUS TO DLC8 - New antiviral peptides interfering the binding of the virus to DLC8. A high number of pathogenic agents of viral origin use the dynein based intracellular transport machinery at some point of their infective cycle. The present invention consists of a new antiviral therapy consisting in the inhibition of viral infections produced by those virus that use the dynein system by mechanisms of interference mainly by preventing the interaction between the viral protein and the cellular DLC8 protein. The present invention discloses for the first time the blocking of the function of this interaction by peptides whose sequence comprises or consists of the totality or a partial sequence of the viral protein corresponding to the binding domain with DLC8. | 11-15-2012 |
20120295841 | Sanglifehrin Based Compounds - There are provided inter alia compounds of formula (I) | 11-22-2012 |
20120329705 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 12-27-2012 |
20130023463 | HIV PROTEASE INHIBITING COMPOUNDS - A compound of the formula | 01-24-2013 |
20130053306 | USE OF HISTONES FOR THE EARLY DIAGNOSIS AND/OR PREVENTIVE THERAPY OF VIRALLY-INFECTED LIVING CELLS AND A BIOCHIP FOR CARRYING OUT SAID DIAGNOSIS - There is provided a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified after viral infection. The agent includes at least one component, selected from a group of materials, including recombinant human histone H1 or at least an H1 subtype or the active portion thereof. The appropriate biological activity for killing a virally-infected cell at the modified cell membrane thereof through cooperation with similarly or differently active agent components may be achieved, which together form a biologically-effective complex with increased biological activity. | 02-28-2013 |
20130059776 | Antiviral Cell-Penetrating Peptides - Disclosed herein are cell penetrating peptides useful as treatment for Human Immunodeficiency Virus. | 03-07-2013 |
20130065819 | TARGET OF EGR1 (TOE1) POLYPEPTIDES FOR INHIBITION OF HIV - Described are methods and compositions for preventing and/or treating HIV infection, as well as in vitro and in vivo methods of inhibiting HIV replication, inhibiting HIV viral transcription, inhibiting the viral Tat protein, and inhibiting HIV LTR expression. The methods involve administering a Target of Egr1 (TOE1) polypeptide, fragment or deletion mutant thereof, either to a subject in need of treatment or to a cell infected with an HIV virus. Compositions may comprise the described polypeptide, or an encoding polynucleotide thereof. | 03-14-2013 |
20130085097 | PAPILLOMAVIRUS VIRUS-LIKE PARTICLE OR CAPSOMERE FORMULATION AND ITS USE AS MICROBICIDE - Methods and compositions for preventing viral infection are disclosed. Compositions containing papillomavirus VLPs or capsomeres are used, alone or in combination with other agents, as microbicides that substantially block papillomavirus binding receptors on the surface or vicinity of cells in a tissue to be treated with the composition. The invention can be used to inhibit papillomavirus infection or infection by another virus that utilizes the same binding receptors during the infection process. | 04-04-2013 |
20130109619 | PEPTIDE-BASED INHIBITOR OF INTERLEUKIN-10 OR INTERFERON-GAMMA SIGNALING | 05-02-2013 |
20130130971 | Method for Inhibiting HIV Replication in Mammal and Human Cells - The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton. | 05-23-2013 |
20130143795 | METHOD OF TREATMENT OF HIV OR AIDS - The invention relates to a method of treating HIV or AIDS comprising administering a composition comprising a polypeptide comprising LKKTETQ (SEQ ID NO: 1) or a variant thereof, or administering a composition comprising a peptidomimetic of a polypeptide comprising amino acid sequence LKKTETQ (SEQ ID NO: 1) or a variant thereof. | 06-06-2013 |
20130184202 | Peptide Inhibitors and Methods of Use Thereof - Peptides and methods of use thereof are provided. | 07-18-2013 |
20130196903 | Multimeric Inhibitors of Viral Fusion and Uses Thereof - The present invention relates to novel multimeric inhibitors of viral entry into cells and their use for the prophylaxis and treatment of viral infections. | 08-01-2013 |
20130210709 | CXCR4 Receptor Compounds - The invention relates generally to compounds which are allosteric modulators (e.g., positive and negative allosteric modulators, and allosteric agonists) of the G protein coupled receptor for stromal derived factor 1 (SDF-I), also known as the CX-CR4 receptor. The CXCR4 receptor compounds are derived from the intracellular loops and domains of the CXCR4 receptor. The invention also relates to the use of these CXCR4 receptor compounds and pharmaceutical compositions comprising the CXCR4 receptor compounds in the treatment of diseases and conditions associated with CXCR4 modulation such as bone marrow trans-plantation, chemosensitization, cancer, metastatic disease, inflammatory diseases, HIV infection and stem cell-based regenerative medicine. | 08-15-2013 |
20130267461 | COMPOUNDS AND THERAPEUTIC APPLICATIONS RELATED TO INHIBITION OF DENDRITIC CELL IMMUNORECEPTOR (DCIR) ACTIVITY AND SIGNALING EVENTS - The invention is concerned with methods, compounds and pharmaceutical compositions for interfering dendritic cell immunoreceptor (DCIR) activity and signalling events. Described herein are compounds useful in targeting one or more of intracellular modulators and the uses thereof for the prevention or treatment of virus infections, and more particularly for reducing human immunodeficiency virus (HIV) binding, entry and/or replication in human cells. Exemplary compounds include peptides and antisense molecules. | 10-10-2013 |
20130274177 | MAMMALIAN COLOSTRUM DERIVED NANOPEPTIDES FOR BROADSPECTRUM VIRAL AND RECURRENT INFECTIONS WITH A METHOD OF ISOLATION THEREOF - The present Invention relates to nanopeptides isolated from mammalian colostrums with vaccine like antiviral and immunodulator activity via building body's own immune system and attachment inhibition on the cell surface receptors. | 10-17-2013 |
20130274178 | Active Cores of Peptide Triazole HIV-1 Entry Inhibitors - The invention provides a peptide triazole conjugate and derivatives thereof, and methods of its use. The invention also provides an antibody to the peptide triazole conjugate. The invention further provides a method of identifying an HIV-1 entry inhibitor candidate. | 10-17-2013 |
20130316944 | ENGINEERED CXCL12 ALPHA LOCKED DIMER POLYPEPTIDE - The present invention provides a novel CXCL12-α | 11-28-2013 |
20130324459 | Compounds For Enzyme Inhibition - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 12-05-2013 |
20140005100 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION | 01-02-2014 |
20140005101 | Oligoadenylate Synthetase (OAS) | 01-02-2014 |
20140005102 | Oligoadenylate Synthetase (OAS) | 01-02-2014 |
20140011735 | ANTIVIRAL COMPOSITION - The present invention provides a composition comprising a broad spectrum protein of microbial origin as active anti-HIV/AIDS agent. Either the protein is secreted by or surface associated in microorganisms including but not limiting to bacteria, both pathogenic and non-pathogenic. The proteins used are isolated from bacteria | 01-09-2014 |
20140018288 | X-DING-CD4 Peptide - Here provided are a pharmaceutical composition containing an X-DING-CD4 peptide, a derivative of the X-DING-CD4 peptide, or a combination thereof a method for preventing or treating a pathological condition in a subject using the above pharmaceutical composition; and a process of making the above pharmaceutical composition. Also provided are isolated X-DING-CD4 cDNAs and isolated X-DING-CD4 peptides. Further provided are the composition and method for cell-based therapy using polynucleotides encoding X-DING-CD4 peptide, its derivative, or a combination thereof. | 01-16-2014 |
20140038884 | ANTIVIRAL PEPTIDES - The present invention relates to selected proline-rich peptides of salivary derivation with a strong antiviral activity and also an anti-reservoir activity with respect to the HIV virus, said peptides as medicaments for the treatment, prevention and eradication of HIV on human beings, pharmaceutical compositions comprising at least one of said peptides, pharmaceutical kits comprising at least one of said peptides and therapeutic methods for the treatment, prevention and eradication of HIV on human beings. | 02-06-2014 |
20140038885 | Macrocyclic Compounds and Methods for Their Production - There is provided inter alia compounds of formula (I): | 02-06-2014 |
20140057834 | Cell-Permeable Peptide Inhibitors of the JNK Signal Transduction Pathway - The invention provides cell-permeable peptides that bind to JNK proteins and inhibit JNK-mediated effects in JNK-expressing cells. | 02-27-2014 |
20140066366 | Use Of Histones For The Early Diagnosis And/Or Preventive Therapy Of Virally-Infected Living Cells - There is provided a biologically-active agent, in particular, for the early diagnosis and/or preventative therapy of virally-infected living cells, the efficacy of which is selective for the cell membranes of the virally-infected cells, which are modified after viral infection. The agent includes at least one component, selected from a group of materials, including recombinant human histone H1 or at least an H1 subtype or the active portion thereof. The appropriate biological activity for killing a virally-infected cell at the modified cell membrane thereof through cooperation with similarly or differently active agent components may be achieved, which together form a biologically-effective complex with increased biological activity. | 03-06-2014 |
20140094404 | METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLS - The invention relates to conjugates comprising a targeting moiety specific for the CXCR4 based on the polyphemusin-derived peptide and a therapeutic or imaging agent. The invention relates as well to the application of said conjugates for the therapy and diagnostics which require the specific targeting to CXCR4+ cells. | 04-03-2014 |
20140094405 | CHOLESTEROL DERIVATIVES OF INHIBITORS OF VIRAL FUSION - The present invention relates to compounds comprising at least ten contiguous amino acids of the HR2 domain of a Type 1 viral fusogenic protein of an enveloped virus, or a derivative thereof, attached at the C-terminal to cholesterol or a derivative thereof; or a pharmaceutically acceptable salt thereof which inhibit viral fusion. Thus compounds of the invention are useful to prevent or treat diseases caused by an enveloped virus. | 04-03-2014 |
20140107015 | PHARAMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING HUMAN IMMUNODEFICIENCY VIRUS - There is provided a pharmaceutical composition for preventing or treating human immunodeficiency virus, and more particularly, to a pharmaceutical composition and health functional food for preventing or treating/improving human immunodeficiency virus, the pharmaceutical composition and health functional food including a new compound with chitooligosaccharides conjugated amino acids or dipeptides as an effective component. The new compound has an excellent anti-HIV effect through an activity of inhibiting a HIV initial infection by interrupting an interaction between host-virus membranes, and also activities of inhibiting reverse transcriptase and protease of HIV. The compound according to the present invention is a conjugate synthesized through conjugating chitooligosaccharides derived from a natural material with amino acids or dipeptides. The compound is stable without cytotoxicity. | 04-17-2014 |
20140128316 | INTEGRASE COFACTOR - The present invention provides nucleic acid molecules which include a region specifically interacting with the nucleic acid encoding the LEDGF/P75 protein or the nucleic acid encoding a fragment of a LEDGF/P75 protein and methods and uses of such nucleic acid molecules. | 05-08-2014 |
20140142033 | CYCLOSPORINE ANALOGUE MOLECULES MODIFIED AT AMINO ACID 1 AND 3 - Analogues of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1. | 05-22-2014 |
20140148381 | MODIFIED VIRAL STRUCTURAL PROTEIN WITH ANTIVIRAL ACTIVITY - This disclosure provides a novel strategy to cope with chronic virus infection by introducing a dominant negative viral structural protein to disturb effective virion production. The dominant negative structural protein mimics antiviral drugs through structural and biochemical interactions during virus assembly. An effective gene therapy model for chronic viral infected diseases is proposed in this disclosure, as represented by HBV Cpdominant 1 to clear viral infection. | 05-29-2014 |
20140187476 | PEPTIDE DERIVATIVE FUSION INHIBITORS OF HIV INFECTION - This invention relates to gp41 peptide derivatives that are inhibitors of viral infection and/or exhibit antifusogenic properties. In particular, this invention relates to gp41 derivatives having inhibiting activity against human immunodeficiency virus (HIV) and simian immunodeficiency virus (SIV) with enhanced duration of action for the treatment of the respective viral infections. | 07-03-2014 |
20140187477 | INHIBITORS OF VIRAL INTEGRASE AND METHODS OF USE - Described herein are compositions and methods for inhibiting HIV integrase activity. Also described are methods of identifying agents that inhibit HIV integrase for use in treating or preventing HIV. Also disclosed are methods of identifying agents that inhibit HIV viral mutants that are resistant to integrase inhibitors. | 07-03-2014 |
20140194349 | HIV Protease Inhibiting Compounds - A compound of the formula | 07-10-2014 |
20140213508 | ANTIVIRAL MACROCYCLES - Cyclosporin derivatives, methods of manufacturing the cyclosporin derivatives and methods for treating subjects infected with certain viruses, including hepatitis virus or HIV by administering the cyclosporin derivatives are described. | 07-31-2014 |
20140213509 | BETA-HAIRPIN PEPTIDOMIMETICS AS CXC4 ANTAGONISTS - β-Hairpin peptidomimetics of the general formula cyclo(-Tyr | 07-31-2014 |
20140287990 | COMPOSITIONS AND METHODS TO CONCURRENTLY TREAT AND/OR PREVENT MULTIPLE DISEASES WITH CUPREDOXINS - The present invention relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to treat and/or prevent two or more conditions in a mammalian cell. The invention also relates to compositions and methods to administer compositions comprising cupredoxin and/or cytochrome and/or variants, derivatives, truncations and structural equivalents of cupredoxin and cytochrome to concurrently treat and/or prevent two or more conditions in a patient such as HIV, cancer, malaria and inappropriate angiogenesis. | 09-25-2014 |
20140303074 | Compositions and Methods For Inhibiting Immunodeficiency Virus Transcription - The present disclosure provides methods of reducing immunodeficiency virus transcription, involving use of diflunisal or an active ester thereof. The disclosure also provides methods of treating an immunodeficiency virus infection in an individual, the method generally involving administering to the individual an effective amount of diflunisal or an active ester thereof. | 10-09-2014 |
20140309163 | FIBRONECTIN BASED SCAFFOLD DOMAIN PROTEINS THAT BIND TO MYOSTATIN - The present invention relates to fibronectin-based scaffold domain proteins that bind to myostatin. The invention also relates to the use of these proteins in therapeutic applications to treat muscular dystrophy, cachexia, sarcopenia, osteoarthritis, osteoporosis, diabetes, obesity, COPD, chronic kidney disease, heart failure, myocardial infarction, and fibrosis. The invention further relates to cells comprising such proteins, polynucleotides encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the proteins. | 10-16-2014 |
20140315791 | METHOD OF MAKING BIOLOGICALLY ACTIVE ALPHA-BETA PEPTIDES - Described is a method of fabricating biologically active, unnatural polypeptides. The method includes the steps of selecting a biologically active polypeptide or biologically active fragment thereof having an amino acid sequence comprising α-amino acid residues, and fabricating a synthetic polypeptide that has an amino acid sequence that corresponds to the sequence of the biologically active polypeptide, but wherein about 14% to about 50% of the α-amino acid residues found in the biologically active polypeptide or fragment of step (a) are replaced with β-amino acid residues, and the α-amino acid residues are distributed in a repeating pattern. | 10-23-2014 |
20140323394 | TRIPEPTIDE KDPT FOR ANTIAPOPTOTIC TREATMENT - The present invention is related to the tripeptide (I)Lys-(d)Pro-(I)Thr (KdPT) or pharmaceutically acceptable salts thereof for therapeutic, prophylactic therapeutic or cosmetic treatment of a disease with increased apoptosis, wherein the treatment has an anti-apoptotic effect. The present invention is also related to the use of KdPT or pharmaceutically acceptable salts thereof for the manufacture of a pharmaceutical or cosmetic composition for an anti-apoptotic treatment of disorders that are related with increased apoptosis. | 10-30-2014 |
20140342977 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 11-20-2014 |
20140349919 | CHROMANE-LIKE CYCLIC PRENYLFLAVONOIDS FOR THE MEDICAL INTERVENTION IN NEUROLOGICAL DISORDERS - The present invention relates to certain chromane-like cyclic prenylflavonoids, in particular the compounds of formulae (I), (II) and (III) as described and defined herein, for use in the treatment or prevention of a neurological disorder, as well as their use in promoting neuronal differentiation, neurite outgrowth and neuroprotection. | 11-27-2014 |
20140349920 | N-ACYLPEPTIDE DERIVATIVES AND THEIR USES - N-acylpeptide derivatives are described. Compositions comprising N-acylpeptide derivatives are therapeutically effective for topical or systemic administration to alleviate or improve conditions, disorders, diseases, symptoms or syndromes associated with tumors or cancers, immune, nervous, vascular, musculoskeletal, cutaneous system, or other tissues or systems in a subject. | 11-27-2014 |
20140364360 | GLYCOSAMINOGLYCANS FOR CHEMOKINE DRUG DELIVERY - A pharmaceutical composition for sustained release of a chemokine is described that includes a polymer bonded to a sulfated glycosaminoglycan and loaded with a chemokine having affinity for the sulfated glycosaminoglycan. The pharmaceutical composition can be used in a method for providing sustained release of a chemokine to subject by contacting the subject with the pharmaceutical composition. | 12-11-2014 |
20140371136 | GROWTH HORMONE POLYPEPTIDES AND METHODS OF MAKING AND USING SAME - The present invention relates to compositions comprising growth hormone linked to extended recombinant polypeptide (XTEN), isolated nucleic acids encoding the compositions and vectors and host cells containing the same, and methods of making and using such compositions in treatment of growth hormone-related diseases, disorders, and conditions. | 12-18-2014 |
20150011466 | APJ Receptor Compounds - The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection. | 01-08-2015 |
20150045291 | LIPOPEPTIDE CONJUGATES COMPRISING SPHINGOLIPID AND HIV GP41 DERIVED PEPTIDES - The invention provides conjugates comprising a short isolated peptide coupled to a sphingolipid, the peptide comprising a sequence derived from the HIV-1 gp41. The sphingolipid-peptide conjugates are suitable for treatment of infections caused by human and non-human retroviruses, especially HIV. | 02-12-2015 |
20150111814 | NOVEL COMPOSITIONS FOR PROMOTING HIV-1 VIROLYSIS AND METHODS USING SAME - The present invention includes compounds that are useful for treating or preventing a HIV-1 infection in a mammal. In certain embodiments, the compounds cause cell-free virolysis of an HIV-1 virus. The presented invention further includes a method of causing virolysis of a virus using the compounds described therein. The presented invention further includes a method of treating or preventing an HIV-1 infection in a mammal in need thereof using the compositions described therein. | 04-23-2015 |
20150111815 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS - The present invention relates to a compound of formula (I): | 04-23-2015 |
20150119317 | ORAL SOLID DOSAGE FORMULATION OF 1,1-DIMETHYLETHYL [(1S)-1-CARBAMOYL)PYRROLIDIN-1-YL]CARBONYL}-2,2-DIMETHYLPROPYL]CARBAMATE - The present invention is directed to an oral solid dosage formulation of Asunaprevir, 1,1-dimethylethyl[(1S)-1-{[(2S,4R)-4-(7-chloro-4methoxyisoquinolin-1-yloxy)-2-({(1R,2S)-1-[(cyclopropylsulfonyl)carbamoyl]-2-ethenylcyclopropyl}carbamoyl)pyrrolidin-1-yl]carbonyl}-2,2-dimethylpropyl]carbamate, and to methods of using the formulation in the treatment and/or inhibition of the hepatitis C virus and infections caused thereby. | 04-30-2015 |
20150306174 | Trimeric HIV Fusion Inhibitors for Treating or Preventing HIV Infection - Disclosed herein are trimeric polypeptide pharmaceutical compositions comprising three monomers, each monomer comprising a polypeptide having the amino acid sequence of the N-terminal heptad repeat (NHR or HR1) or C-terminal heptad repeat (CHR or HR2) of the transmembrane glycoprotein of human immunodeficiency virus (HIV) and a trimerization motif. | 10-29-2015 |
20150344535 | NEUROTROPHIN-TYROSINE KINASE RECEPTOR SIGNALING - The invention relates to a method of regulating neurotrophin-tyrosine kinase receptor signaling in a cell comprising modulating the interaction between the juxtamembrane region of the intracellular domain of the neurotrophin receptor p75 and Trk. The invention also relates to compositions comprising compounds which modulate the interaction between the juxtamembrane region of the intracellular domain of the neurotrophin receptor p75 and Trk, and use of the compounds and compositions for the treatment of neurotrophin-Trk signaling related diseases and disorders. | 12-03-2015 |
20150361134 | COMPOUNDS FOR PROTEASOME ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. | 12-17-2015 |
20150361152 | MONOMERIC CXCL121 PEPTIDE AND METHODS OF SYNTHESIS AND USE THEREOF - The present invention provides a CXCL12 | 12-17-2015 |
20150374840 | MODIFIED PEPTIDES AND PROTEINS - Provided are compounds and methods of making compounds containing two or three groups derived from a peptide, such as enfuvirtide or exenatide, covalently bound to a linker. The compounds may contain polyethylene glycol groups to enhance solubility and pharmacokinetic properties. The compounds are useful for the treatment of diseases or conditions subject to treatment with the parent peptide, such as HIV and AIDS in the case of enfuvirtide, or diabetes in the case of exenatide. | 12-31-2015 |
20160002299 | NON-IMMUNOSUPPRESSIVE CYCLOSPORIN DERIVATIVES AS ANTIVIRAL AGENTS - A cyclosporin derivative which is a compound of formula (I), or a pharmaceutically acceptable salt thereof, for use in the treatment or prevention of a viral infection: wherein: A represents (F(II)) or (F(III)) B represents methyl or ethyl, R | 01-07-2016 |
20160002304 | TREATING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS - The specification provides methods and compositions for determining a prognosis for a subject infected with HIV, reducing a risk of an HIV infection, and treating or reducing a risk of developing AIDS. | 01-07-2016 |
20160016999 | INHIBITORY PEPTIDES OF VIRAL INFECTION - Disclosed are methods of treating and/or inhibiting a viral infection in a subject. The methods include administering a therapeutically effective amount of heparin-binding peptide. Also disclosed herein are methods for blocking viral binding to a cell. Further disclosed are anti-viral compositions for administration to a subject infected with a virus. Administration of the anti-viral composition inhibits viral infection of the subject. | 01-21-2016 |
20160024149 | BIOACTIVE MOLECULES PRODUCED BY PROBIOTIC BACTERIA AND METHODS FOR ISOLATING AND USING THE SAME - The present invention is a method for isolating bioactive molecules secreted by probiotic bacteria such as | 01-28-2016 |
20160030518 | COMPOSITIONS AND METHODS FOR INHIBITING VIRAL ACTIVITY - The present disclosure provides methods of inhibiting viral activity in a cell, the methods generally involving contacting the cell with a soluble CD137 polypeptide or a FAM3C polypeptide. The present disclosure provides methods for treating a virus infection in an individual, the methods generally involving administering to the individual an effective amount of a soluble CD137 polypeptide or a FAM3C polypeptide. | 02-04-2016 |
20160032263 | HIV-1 INTEGRASE DERIVED PEPTIDES AND COMPOSITIONS - Isolated peptides comprising sequences derived from the protein integrase of HIV-1, as well as their analogs, mixtures, conjugates with permeability enhancing moieties, and pharmaceutical compositions are disclosed. The peptides and compositions are capable of selectively killing HIV-1 infected cells and are used in treatment of HIV infection and AIDS. | 02-04-2016 |
20160040165 | COMPOSITIONS AND METHODS FOR IN VIVO EXCISION OF HIV-1 PROVIRAL DNA - Methods and kits for excising HIV-1 DNA in vivo are provided, which employ Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) and CRISPR-Associated (cas) proteins. Vectors harboring nucleic acids encoding one or more guide RNA, wherein said guide RNA hybridizes with a target HIV-1 DNA are also provided. | 02-11-2016 |
20160052972 | NOVEL CYCLOSPORIN DERIVATIVES FOR THE TREATMENT AND PREVENTION OF A VIRAL INFECTION - The present invention relates to a compound of the formula (I): | 02-25-2016 |
20160052979 | FAMILY OF SYNTHETIC POLYNUCLEOTIDE-BINDING PEPTIDES AND USES THEREOF - The present invention provides novel synthetic peptides (including the TZIP peptide) as oncogenic and genetic modulators, including genetics of viruses, as well as methods of making and using the same. These peptides are useful for inhibiting the proliferation of cancer cells characterized as having amplified c-MYC genes. The invention provides methods for the therapeutic uses of the peptides in the treatment of various cancers including small cell lung carcinoma, prostate cancer, lymphoma, brain tumors, colon cancer, bladder cancer, AML, malignant melanoma, mesothelioma, and cancers of head and neck. The peptides are also useful in the treatment of and prevention of transmission of HIV and treatment of expanded nucleotide repeat diseases, including certain currently untreatable and debilitating diseases. | 02-25-2016 |
20160083421 | COMPUNDS FOR ENZYME INHIBITION - Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases associated with the proteasome. The peptide-based compounds include an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. Oral administration of these peptide-based proteasome inhibitors is possible due to their bioavailability profiles. | 03-24-2016 |
20160101150 | PEPTIDES HAVING ANTI-INFLAMMATORY PROPERTIES - Aspects of the present invention relate to peptides having anti-inflammatory activity, compositions containing one or more of the peptides, and use of the peptides to treat conditions associated with excessive inflammation in animals, particularly humans and other mammals. | 04-14-2016 |
20160106810 | Method for Inhibiting HIV Replication in Mammal and Human Cells - The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-10. The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton. | 04-21-2016 |
20160115204 | METHODS FOR PREPARING PURIFIED POLYPEPTIDE COMPOSITIONS - The present invention relates to purified peptidomimetic macrocycles. The invention additionally provides methods of preparing and using such macrocycles, for example in therapeutic applications. | 04-28-2016 |
20160122401 | AGENTS FOR PREVENTING AND TREATING HIV AND OTHER VIRAL INFECTIONS - An agent for preventing and/or treating HIV and other viral infections. The agent in particular comprises at least one peptide, including an amino acid sequence, which is suitable for preventing fibrils associated with Alzheimer's disease, and/or homologs, fractions and parts thereof, so as to treat and/or prevent HIV and/or other viral infections. | 05-05-2016 |
20160129073 | Method for Inhibiting HIV Replication in Mammal and Human Cells - The present invention describes a method to inhibit replication of the human immunodeficiency virus (HIV) by negatively modulating or altering the cytoskeleton, more precisely the proteins forming the intermediate cytoskeletal filaments, wherein the said proteins are vimentin and/or keratin-la The replication of the virus is inhibited in human cells by intervening in the structure of these proteins. The present invention is also related to the use of agents, which comprise peptides and/or interfering RNA and/or lipidic compounds, said agents producing a negative modulation or alteration of the cytoskeleton to prevent or to treat the HIV infection. The invention provides means and methods for altering the cytoskeleton/filament structure of cells, as a result of which the infection of human cells by HIV is disturbed and can even be completely inhibited. The cytoskeleton is altered by reducing the amount of vimentin and/or keratin (e.g. by transcriptional control using interfering RNA) or by using peptides that disrupt the cytoskeleton. | 05-12-2016 |
20160151511 | PROTEINS AND PROTEIN CONJUGATES WITH INCREASED HYDROPHOBICITY | 06-02-2016 |
20160152676 | HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONS | 06-02-2016 |
20160159861 | APJ Receptor Compounds - The invention relates generally to compounds which are allosteric modulators (e.g., negative and positive allosteric modulators, allosteric agonists, and ago-allosteric modulators) of the G protein coupled receptor apelin, also known as the APJ receptor. The APJ receptor compounds are derived from the it intracellular loop and domain of the APJ receptor. The invention also relates to the use of these APJ receptor compounds and pharmaceutical compositions comprising the APJ receptor compounds in the treatment of diseases and conditions associated with APJ receptor modulation, such as cardiovascular diseases, (e.g., hypertension and heart failure, such as congestive heart failure), cancer, diabetes, stem cell trafficking, fluid homeostasis, cell proliferation, immune function, obesity, metastatic disease, and HIV infection. | 06-09-2016 |
20160193292 | Cell Permeable Inhibitors Of The Scaffold Protein Plenty Of SH3 Domains (POSH) Or Sh3Rfl | 07-07-2016 |
20170233434 | METHOD FOR SEPARATING PROTEINS FROM ANIMAL OR HUMAN PLASMA, OR PLANTS, USING A PH GRADIENT METHOD | 08-17-2017 |